| Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. | |
| | |
MedLine Citation:
|
PMID: 22888106 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
RATIONALE: Patients with cystic fibrosis (CF) experience frequent pulmonary exacerbations (PExs). Clinicians manage these episodes of worsening signs and symptoms in a variety of ways. OBJECTIVES: To characterize the antibiotic management and associated change in lung function following PExs. METHODS: We used 2003-2005 data from the Epidemiologic Study of Cystic Fibrosis to examine antibiotic treatment and the immediate and long-term lung function change associated with clinician reported PExs. RESULTS: A total of 45,374 PExs were reported in 13,194 unique patients. Most PExs (73%) were treated with oral antibiotics, while 39% were treated IV and 24% were treated with inhaled antibiotics. The likelihood of non-IV versus IV antibiotic treatment was associated with the patient's age, stage of lung disease, and magnitude of lung function drop prior to the PEx. Following treatment, the average improvement in the FEV(1) was 3.4 ± 12.2% predicted with a greater (5.1 ± 12.7% predicted) improvement following IV antibiotic treatment than with non-IV treatment (2.0 ± 11.6% predicted). When the best FEV(1) from the year before was compared with 180 days following the PEx there was an average fall of 3.8 ± 10.5% predicted with little difference observed between antibiotic treatment routes. Patients with only one exacerbation during the 3-year study had a similar loss of lung function to patients with no reported exacerbations. CONCLUSION: Clinicians treat the majority of PExs with oral antibiotics, particularly in younger, healthier patients. Pulmonary function improves with antibiotic therapy, however, PExs are associated with lung function deterioration over time. Pediatr Pulmonol. © 2012 Wiley Periodicals, Inc. |
| | |
Authors:
|
Jeffrey S Wagener; Lawrence Rasouliyan; Donald R Vandevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan; |
Related Documents
:
|
8266016 - Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduo... 17488406 - Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. 15134386 - A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavio... 7829176 - Effect of flurbiprofen sodium on pupillary dilatation during scleral buckling surgery. 9773696 - The paravertebral nerve root block for inguinal herniorrhaphy--a comparison with the fi... 23349556 - Shoulder function after selective and superselective neck dissections: clinical and fun... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-8-8 |
Journal Detail:
|
Title: Pediatric pulmonology Volume: - ISSN: 1099-0496 ISO Abbreviation: Pediatr. Pulmonol. Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-8-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8510590 Medline TA: Pediatr Pulmonol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Wiley Periodicals, Inc. |
Affiliation:
|
University of Colorado School of Medicine, Aurora, Colorado. jeffrey.wagener@ucdenver.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Practicability of nitrogen multiple-breath washout measurements in a pediatric cystic fibrosis outpa...
Next Document: Chemometrics applications in biotech processes: Predicting column integrity and impurity clearance d...